To cite: Henshall C, Narendran P, Andrews RC, et al. Qualitative study of barriers to clinical trial retention in adults with newly diagnosed type 1 diabetes. BMJ Open 2018;8:e022353. doi:10.1136/bmjopen-2018-022353

ABSTRACT

Objectives Regular physical exercise may preserve β cell function in newly diagnosed adults with type 1 diabetes (T1D). However, clinical trials to test this hypothesis require the recruitment and retention of adults with new-onset T1D, which can be challenging. We sought to determine the overall experiences of newly diagnosed adults with T1D in an exercise study, to understand issues that influence the retention of trial participants in such studies.

Design Qualitative methodology using individual face-to-face (n=6) and telephone interviews (n=14). Interview transcripts were thematically analysed using the framework method.

Setting The study took place at five participating UK hospitals.

Participants Twenty participants, aged 19–55 years, in the Exercise for Type 1 Diabetes study were interviewed to explore their study experiences and identify motivators and deterrents towards the study. Participants in control and intervention arms were interviewed, as were people with T1D who had completed (n=16) and withdrawn (n=4).

Results Participants revealed barriers and facilitators to retention; the majority were generalisable to clinical trials of people with newly diagnosed T1D. Coming to terms with a diagnosis of T1D, lack of time, work pressures, level of health professional support, volume, clarity and consistency of information and feedback and a desire for knowledge about their condition were all cited as influencing factors to trial retention.

Conclusions To our knowledge, this is the first qualitative study to examine the experience of being involved in an exercise trial by people with T1D. Findings suggest appointments could be shorter, available outside of working hours and planned longer in advance; study information should be clear, consistent and in electronic and paper formats; questionnaires need minimising; healthcare support and feedback needs providing regularly; thought is required around how to support non-exercising arm participants. These considerations may improve participant retention rates in new-onset T1D studies.

INTRODUCTION

Type 1 diabetes (T1D) is a chronic autoimmune condition characterised by immune-mediated destruction of insulin-producing pancreatic β cells. Significant numbers of β cells are present at the time of diagnosis, and preservation of β cell function is associated with significant benefits for people with T1Ds. Interventions that can preserve residual β cell function in new-onset T1D are needed.

In animal models of T1D and type 2 diabetes (T2D), healthy humans and in people with impaired glucose tolerance with T2D, regular exercise has been shown to preserve β cell function. These findings have not been tested in people with T1D, and there is thus a need for a prospective clinical trial to test the hypothesis that exercise preserves β cell function in people newly diagnosed with T1D.

The Exercise for Type 1 Diabetes (EXTOD) study was a pilot study undertaken to explore whether exercise can preserve β cell function in adults newly diagnosed with T1D. In designing this study, we had to bear in mind that the incidence rate of T1D is low and recruitment of people with T1D to clinical trials is challenging. Other studies have shown recruitment rates as low as 17%. This means that retaining people with newly diagnosed T1D who are recruited to studies is even more important. In studies of immunotherapeutic agents for T1D, dropout rates are 12%–14%.; however, higher rates have
been reported for exercise studies. In a meta-analysis of unsupervised exercise programmes for people with T2D, 20% of studies had a dropout of >20%, 32% a dropout of 10%–20% and 48% a dropout of <10%.9

Barriers to participation in clinical trials are well documented,10 although no studies have looked at barriers to recruitment in people with T1D. There are very few studies that have looked at how to improve retention rates of people with T1D in a clinical randomised controlled trial (RCT). Those studies that have been done have concentrated on strategies to improve retention rather than barriers to retention.11 No studies have looked at barriers to retention in people newly diagnosed with T1D. We wished to address this important deficit by qualitatively exploring the experiences of people with newly diagnosed T1D who participated in a recently completed exercise and T1D study.12 Here we report our findings from a qualitative study of barriers to clinical trial retention in adults with recently diagnosed T1D. We have not reported other findings from the EXTOD study, which are reported separately.13 14

**METHODS**

**Setting, access and recruitment**

Study participants were from the EXTOD study, whose protocol has been described previously.12 In brief, all people aged between 16 and 60 years, diagnosed with T1D in the previous three months, from 19 UK hospital sites were invited to participate. The EXTOD study explored the barriers and benefits of exercise in adults with newly diagnosed T1D. The hypothesis being tested by the EXTOD study was that exercise preserved β cell function in adults recently diagnosed with T1D. EXTOD had two phases. Phase I consisted of a qualitative study to determine attitudes and barriers to exercise in people with newly diagnosed T1D13. Phase II was a pilot RCT to assess uptake, intervention adherence, dropout rates and rate of uptake in the usual care group during a 12-month exercise intervention (where the participants came from for this study).

At the time of recruitment to the pilot RCT (phase II) study, all people with T1D received participant information leaflets and provided informed consent to potentially take part in an interview to explore their experience of being involved in the pilot RCT. Of the 60 participants who took part in the pilot RCT, 20 participants from five participating sites (Birmingham, Leeds, Bristol, Gloucester, Taunton) were later selected using purposive sampling to ensure variety and diversity in terms of their key study characteristics.15 Participants were sampled in relation to their age, gender, study arm (intervention/control) and study status (completed/withdrawn) to ensure that an even spread of participants across the key characteristics were sampled. Similarly the sites were selected to allow a purposeful sampling of geographical areas participating in the EXTOD study (teaching hospitals vs district general hospitals). Selected participants were sent a letter at the end of the pilot RCT, informing them that they would be contacted by the EXTOD team. This was followed, a week later, by a phone call from a member of the EXTOD team (nurse or doctor) to check they were happy to be interviewed. If willing, they were then telephoned by the researcher (CH), who has a nursing background and is an experienced qualitative researcher (though she had not previously undertaken any research in this area), to arrange a suitable time and date for her to undertake the interview. CH had had no contact with participants prior to this and participants were unaware of the researcher’s background. All participants agreed to be interviewed.

**Patient involvement**

The research question was derived from people with T1D attending clinic and asking clinicians about any benefits and barriers to exercise as they were aware that much work had been undertaken on this topic in people with T2D, but not in people with T1D. This led to the formulation of the research question and an application for funding to undertake this research. People with T1D were involved in the study design from the outset as the researchers presented the study proposal to them and asked for any comments relating to it (approximately seven people with T1D were involved). Issues relating to the conduct of the study, such as the potential burden of the exercise intervention to participants, were also discussed and any feedback was incorporated into the study design. People with T1D also contributed to the study conduct by sitting on the study management committee and helping with study oversight, including helping to develop approaches to improve study recruitment (three people with T1D were involved). Study findings for phase II of the study were fed back to participants through an informal feedback evening where the findings were presented. This was well received by the participants. In addition, a summary of findings was posted to participants.

**Data collection**

Participants at the hospital where the researcher was based (Birmingham) were given the option of being interviewed face-to-face at the hospital or by telephone. The remaining participants were all interviewed by telephone due to financial, time and travel constraints. All interviews were carried out with only the participant and CH present.

Interviews were carried out by CH using a structured topic guide (table 1) that was developed in consultation with the EXTOD researchers. The interviews lasted between 20 and 50 min. No repeat interviews were conducted. Areas for discussion included levels of health professional support, information provided about diet and exercise and issues relating to recruitment and follow-up. All interviews were digitally recorded and transcribed verbatim by a local transcription company.
Table 1  Topic guide for interview study

| Openers                                                                 | If I could start by asking you how long ago you took part in the study? How did you find the experience? |
|------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------|
| Diet and exercise information                                          | How appropriate was the advice about diet and exercise in relation to its content and volume?              |
|                                                                       | Do you feel being recruited to the study so soon after diagnosis was a good thing or would you have preferred more time? |
|                                                                       | When would have been an appropriate time?                                                                    |
|                                                                       | How well were able to take in the information you were given?                                               |
|                                                                       | Would it have been helpful to see the dietician again, or do you feel that once was enough?                  |
|                                                                       | Did you refer to the study information booklet? If so, how helpful was the information booklet?               |
|                                                                       | Which sections of the booklet particularly helpful or unhelpful?                                            |
|                                                                       | Do you use the booklet as a reference guide now?                                                            |
|                                                                       | Did any aspects of your diet change following looking at the information booklet?                            |
|                                                                       | Can you think of any better ways in which the information could have been delivered?                        |
| Health professional support                                            | How well supported did you feel in terms of the clinical support you received?                              |
|                                                                       | Did you feel you more or less well supported through being on the trial?                                    |
|                                                                       | Do you feel being in the trial was better or worse in terms of the number of doctors/nurses you saw? Why?   |
|                                                                       | Were you happy seeing the same nurse all the way through the trial or would you have preferred more variety?|
|                                                                       | Did you mind no longer seeing the nurse you saw when you were diagnosed?                                    |
|                                                                       | Did you mind not seeing these study doctors/nurses on a regular basis now?                                 |
|                                                                       | How well balanced were the follow-up visits in terms of the health professional you saw? Would you have     |
|                                                                       | preferred more/less visits with a doctor/nurse etc… Or do you feel it was the right amount of time with each?|
|                                                                       | Overall, how well supported by the doctors and nurses did you feel?                                         |
| Recruitment and follow-up                                              | Where did you first hear about the trial from? Who approached you?                                          |
|                                                                       | What appealed to you about taking part in the study in the first place? What were your reasons?              |
|                                                                       | Was there anything that put you off taking part in the study?                                              |
|                                                                       | How easy to complete and understand were the questionnaires you received?                                   |
|                                                                       | During the trial you were required to have extra blood tests. How did you feel about having the extra bloods?|
|                                                                       | How much did you feel the follow-up visits were focused on you and how much did you feel they were focused on the trial and form filling etc… Was this appropriate or could it be weighted differently? |
|                                                                       | Would you have preferred most of the follow-up visits to have taken place face to face or over the phone?   |
|                                                                       | Can you describe whether being on the study affected your confidence levels in terms of undertaking exercise?|
|                                                                       | What were your reasons for leaving the study?                                                               |
|                                                                       | Why did you choose to continue/discontinue with the 5-year follow-up as part of the study?                 |
| Motivational interviewing (intervention group only)                     | How useful do you feel the extra support you were given by the nurse about managing your diabetes and exercising was? What were the pros and cons of talking to the nurse about this? |
|                                                                       | Would it have been helpful to have weekly phone calls from the nurse to check on how you were getting on?   |
|                                                                       | Did the amount of exercise you undertook change as a result of these talks with the nurse or did it stay the same? |
|                                                                       | Did the type of exercise you undertook change or stay the same following (a) diagnosis and (b) the intervention? |
|                                                                       | How much physical activity were you carrying out before your diagnosis compared with (a) during the study and (b) now? Has your exercise levels been maintained post-study? |
|                                                                       | Did you feel more or less confident about carrying out exercise following the intervention with the nurse? |
|                                                                       | What more could have been done to encourage you to exercise?                                              |
|                                                                       | What sort of approach might have worked for you to help you to exercise?                                  |
|                                                                       | Some participants did not make their exercise target. Can you think how we could help them reach this target?|
|                                                                       | What methods did you use to increase your exercise levels?                                                |
| Future development of study                                            | If there was one thing we could do to make the study easier for you to take part in what would it be?      |
|                                                                       | We are planning to undertake a larger scale study similar to the one you have taken part in. What sort of things would you change about the study that might make people want to take part in it more? |
|                                                                       | Overall, what did you feel was good or bad about taking part in the study?                                |
|                                                                       | Do you think you would be more or less likely to participate in clinical trials following this experience? |

Data analysis

Data analysis was carried out during the interview period to enable the interview process to be shaped by the emerging data themes and to identify when saturation had been reached. For example, some participants in the early interviews spoke of how they had struggled to
Henshall C, et al. BMJ Open 2018;8:e022353. doi:10.1136/bmjopen-2018-022353

come to terms with their new T1D diagnosis. As a result, subsequent interviews explored this area in more depth, focusing on the impact this had on their experience of participating in the EXTOD study. An inductive approach to data analysis was taken and themes were derived from the interview dataset. The predetermined topic areas set out in the topic guide (table 1) such as ‘health professional support’ and ‘recruitment and follow-up’ guided the analysis process as much of the data collected focused on these topic areas, enabling the researchers to elicit information that was relevant to the study question. Data were coded by CH and were inserted into a framework analysis matrix Excel spreadsheet, to enable data ordering and synthesis, while retaining the meaning and feeling of the interviewees’ words. Themes were developed by CH by reading and rereading the transcripts and these themes were then agreed during discussions with research team members (CH, PN and SG). The interviews were then analysed using thematic analysis. Transcripts were not returned to participants to comment on during this process.

RESULTS

Participants
In total, 20 participants were interviewed; 6 face-to-face and 14 by telephone (table 2). Participants were recruited from all five participating sites; 11 were men, ages ranged from 19 to 55 years and all were of white British ethnic origin. Thirteen had been allocated to the intervention group and seven to the usual care comparator. Sixteen participants had completed EXTOD, while four had withdrawn for reasons including work commitments, a cancer diagnosis and difficulties accepting their diabetes diagnosis.

Themes
The interviews yielded data on five main themes, and these help formulate the barriers and facilitators to trial participation (Box 1). These themes were study paperwork, feedback, barriers to continued participation, coming to terms with diagnosis of T1D and effect of allocated arm.

Study paperwork
Two main subthemes emerged within the ‘study paperwork’ theme; these were study information and study questionnaires.

Study information
The volume, clarity and consistency of information provided were important in determining how well informed participants felt about their diabetes and its management. Though a few participants felt they were given too much information, most felt that although there was a lot of information, it was useful, relevant and necessary so soon after diagnosis. Generally the information was cited as interesting, manageable and straightforward.
and quality of life that were completed at the study visit. Participants felt that although the paperwork was generally easy to complete and understand, it could also be repetitive, confusing and contradictory, containing irrelevant, non-specific questions, which were hard to relate and respond to.

I remember always getting given the questionnaire sheet when I was having my bloods done. And I could just never fill it in. It used to be like – I used to say to my dad can you ask my questions and then I could do it, but it did go on for quite a while … And it was the same the second time I did it as well, and I was like I don’t know what to put for these questions again. It seemed like I was doing the same thing. EXTOD 19 (female, Birmingham)

Feedback

Some participants voiced disappointment at receiving little trial feedback, stating that the opportunity for feedback had incentivised them to join the trial, as a way of finding out about their diabetes and also that they wanted to learn more about the long-term trial outcomes.

It would be good to have some follow-up information … I wasn’t quite sure how my fitness level was affected … And I never got to find out if it actually improved. EXTOD 1 (female, Birmingham)

Barriers to continued participation

In total, 17 of the 58 participants who were randomised into the original EXTOD study withdrew before the end of the study. We thus sought to understand why this might have happened.

Participants described practical barriers as the most likely reasons for dropping out. These included time and work pressures, dislike of blood tests, travelling to appointments, the long study duration, volume of visits and moving away.

I’m not bothered for taking blood or doing injections or anything like that … But I can remember feeling bothered by that at the time. I think because I was very ill, really, still, and still quite fragile … I can remember that upsetting me … Because it was a study and because I didn’t have to do it … If you volunteered to have a blood test and it takes a few times for them to take the blood, it’s kind of like putting yourself through something difficult that you didn’t really need to do. EXTOD 6 (female, Leeds)

The long study duration also deterred many participants, who felt it was too long to fully commit to, meaning they became less vigilant at attending appointments or completing study documentation due to the repetition involved.

It’s quite long. I think that was quite daunting. It turned out to not really be an issue, but because it’s something that I could kind of blend into my lifestyle...
quite a lot. Because I suppose it didn’t really require any prolonged visits to the clinic or anything because it was mostly just things that I could do myself. But initially that was a bit daunting because it’s a year. EXTOD 16 (male, Bristol)

For most, committing to the EXTOD study had proved difficult, due to the time it required off work. This let to difficulties for participants in ensuring they could always attend appointments and sometimes proved costly due to having to take unpaid leave for study visits.

The time that you’re having to have off work … Often it’s unpaid leave so obviously that can be quite difficult. EXTOD 18 (female, Leeds)

These time pressures had led to two of the interviewed participants withdrawing from EXTOD prior to completion. Solutions to these problems suggested by participants—who had both withdrawn and remained in the study—included offering more flexible appointment times and planning clinic visits further in advance so there was more time to plan around them.

I left … Because I didn’t have enough time … The study is of such a long duration and I just found that too challenging with work … If you had appointments at eight o’clock in the evening every time you needed me then so be it … I have to do a hell of a lot of juggling in order to fit that sort of stuff in. EXTOD 17 (male, Bristol)

Coming to terms with diagnosis of T1D
Some participants spoke of how they had struggled to come to terms with their T1D diagnosis, with one participant citing this as their reason for withdrawing from EXTOD. For this participant, her difficulties coping emotionally with her diagnosis had prompted her doctors to advise her to withdraw.

Don’t think it kind of really sank in as to what I’d been diagnosed with … It had kind of hit me and I wasn’t really dealing with having it … I wasn’t taking my insulin and checking my levels as much … The doctors … Felt that it was best that I was taken off it. EXTOD 4 (female, Birmingham)

Effect of allocated arm
Some participants, who had been allocated the exercise intervention, spoke of difficulties maintaining the level of exercise expected of them due to lack of motivation or the extra time it took.

I think a year in it seemed to get a little bit ‘Oh God I’ve been doing this for a year now’ … A year’s a long time … Because towards the end as well, it was like you had to come in and then I had to do the gym thing, and it was kind of like … ‘oh this is getting really laborious’. EXTOD 2 (male, Birmingham)

Others, in the usual care comparator group, spoke of how this disincentivised them from remaining in EXTOD as they were not receiving the exercise benefits they had hoped for.

The sort of people that … Take part … Are often similar to me in kind of quite wanting to do the exercise, and presumably about half of the time you get randomised into not doing the exercise. And I don’t know whether that’s off-putting as well. EXTOD 16 (male, Bristol)

DISCUSSION
This is the first study to examine the experiences of people with T1D taking part in an exercise intervention trial. The findings have highlighted issues that should be considered when designing clinical trials involving this population group. Clinical trials which reflect the needs, wants and preferences of participants can lead to improvements in retention rates, statistical power and, in the longer term, to studies with more credible findings. The findings suggest that timing is an important consideration for many participants. Many may be offered trial entry shortly after their condition’s onset and may be experiencing multiple health and lifestyle changes and struggling to come to terms with their diagnosis of T1D. This highlights the need for sensitive communication of information from health professionals when introducing clinical trials to adults with T1D as they may be experiencing tensions between not wanting to ‘become’ their new illness or allow it to govern them, while reconciling that they need to be adaptable to their illness if they are going to feel well again. The disappointment of some participants at being allocated the usual care group also highlights the need for a clear explanation of equipoise and other clinical trials terminology, so participants can make informed treatment decisions, minimising the potential for withdrawal rates after randomisation. Additional measures that could help with this are offering the intervention at the end of the study or randomising more to the exercise arm than the control arm, to enable more participants access to the intervention.

The study has illustrated the need for the transmission of clear, relevant and useful information to clinical trial participants. Participants showed preferences for a wide range of delivery modes, including paper formats, websites, apps and internet forums. The use of appropriate, accessible media to convey information effectively and engage with participants is dependent on individual preferences and may be influenced by factors such as age, gender and income. The popularity of apps and multimedia technologies among participants indicates that these modes of information delivery should be incorporated specifically into trials with T1D participants, who are likely to be a younger, more technologically minded population group than trials with T2D participants. Future trial designs could offer paper and electronic
information so participants can use their preferred resource. Similarly, when collecting data, a range of methods could be employed, including paper documentation, spreadsheets, phone apps, emails and websites. Demonstrating versatility and flexibility in data collection techniques may help motivate participants to complete study documentation that they might otherwise omit. The importance of providing regular study feedback to participants should also be considered, through letters, emails and presentations, so that their contribution is acknowledged and valued.23

Finally, the interview findings highlighted that practicalities such as work pressures, time commitments and geographical location influenced participants’ ability to commit to the trial. T1D onset usually occurs at a young age, with most people being diagnosed before 35.24 As a result, people with T1D are likely to have busy lives incorporating work, family and social engagements, making committing to a clinical trial difficult. This is verified by the most common reason cited for the high dropout rate (29%) from EXTOD being time and work commitments. To rectify this, more flexible study visit times could be offered, with the option of attending outside normal working hours, such as evenings and weekends. Additionally, the provision of a timetable of scheduled appointments at the study outset would allow participants to plan for them. Improved hospital transport links could also facilitate ease of study attendance.25 By incorporating a flexible approach to these practical barriers, participants will experience less difficulty in complying with study visits, improving retention rates. Consideration should also ensure that the exercise intervention can be integrated into people’s lifestyles, without adding to their pressurised schedules. This could be done by providing a range of exercise options, in a range of locations and within a realistic time frame, to minimise the likelihood of participants becoming overfaced by the extra commitment they have taken on.

Many of the challenges to clinical trial retention in people with T1D are similar to the challenges facing the general population who are recruited to clinical trials.26–30 The issues and challenges participants faced, such as the long study duration, difficulties completing documentation and time pressures, are also likely to be challenges for the general clinical trials population, including T2D. However, this study has identified that although many of these trial-related issues are not specific to T1D populations, the reasons for these issues are likely to be different. For example, people with T1D or T2D may report that time pressures prevent them from committing to a clinical trial. However, while for the T1D participant time pressures may stem from work priorities, the T2D participant time pressures may stem from regularly caring for grandchildren. By understanding more about the reasons behind these barriers to trial recruitment and retention, trials can be designed to accommodate and facilitate the wants and needs of these different groups. The average age of participants entering clinical trials is >50 years of age.26–31

While there is growing evidence that T1D is diagnosed throughout adult life,32 33 the mean age of the randomised EXTOD participants was 32 years, suggesting that trial retention considerations should focus on needs of younger adult populations. This younger age group is likely to face more difficulties in adhering to rigid time schedules and appointments due to added work, family and social pressures. This is important for clinicians and researchers to acknowledge, allowing them to design T1D studies that will facilitate trial recruitment and retention, by offering more flexible appointment times, out-of-hours services and realistic, manageable exercise schedules. These practical solutions are important considerations for retaining participants in clinical trials and must be valued if rich and full trial datasets are to be obtained. These considerations may also have some relevance for T2D populations, with the average age of onset for this disease getting younger.33 34

When considering study design, thought must be given to how to increase recruitment, as well as how to make the study experience appealing to participants once they have consented. By paying attention to the participant’s perspective, the chances of retaining participants for the study duration will increase, improving trial outcomes and participant satisfaction with trial entry.

Strengths and limitations

The interview participants were selected from five UK hospitals, increasing the transferability of the findings to a range of settings. Participants were purposively sampled, stratifying them according to age, gender, randomisation arm and whether they had completed or withdrawn from the study. This enabled a diverse and comprehensive collection of narratives to be gathered and analysed, enhancing the trustworthiness of the findings. However, although 12% of EXTOD participants recruited were non-white, none of the participants recruited to the qualitative study were non-white. This lack of representation is due to our exclusion of ethnicity as a criterion in our purposive sampling. Although we did not purposefully exclude non-white participants from the sample, the likely reason for their lack of inclusion is because T1D is far more common in white populations than other ethnic groups.35 Additionally, many of the geographical locations we recruited from had a white population of >84%.36–38 Despite this, including ethnicity in our purposive sample could have ensured that non-white populations were represented. In addition, due to the interview participants being situated around the UK, most interviews were conducted by telephone. However, where possible, participants were given the choice of being interviewed face-to-face or by telephone, allowing them to choose the setting they found most relaxing, thus increasing opportunity for open dialogue between interviewees and researchers. The fairly even split between participants choosing face-to-face and telephone interviews suggests that providing a choice of setting may increase recruitment and retention to trials, giving participants the opportunity to select their most comfortable environment.
CONCLUSION

To our knowledge, this is the first qualitative study to examine T1D participants’ experiences of being involved in a clinical trial. Although people may be initially motivated to enter clinical trials for reasons such as altruism and a desire for information, practical factors such as work and time constraints, study duration and financial difficulties often act as deterrents for remaining on trials. Though these issues in themselves are not unique to the T1D population, the reasons for these issues are likely to be different. These reasons need considering when designing T1D clinical trials, to ensure that appropriate modifications are built into the trial design to enable people with T1D to participate with minimal disruption to their lives.

The study findings have highlighted that differences do exist between T1D participants and the general clinical trials population. First, despite T1D increasingly being diagnosed in adult life, the younger adult age of people with T1D at recruitment may make it harder for them to commit to clinical trials due to increased work, family and social pressures; this was verified by study participants. Second, the study has indicated that using multimedia technology might benefit T1D participants, who are used to handling information electronically. It has highlighted that to increase retention to T1D trials improvements to trial design are required. This can be done through providing flexible access to services, clear and relevant study information, documentation and feedback, as well as consistent healthcare support.

Acknowledgements

The authors gratefully acknowledge the time and effort of the participants in this trial. They thank staff and colleagues at diabetes centres at the following hospitals for their help with the recruitment of participants and with undertaking this study: Queen Elizabeth Hospital Birmingham, Magsrove Park Hospital Taunton, Bristol Royal Infirmary, Southmead Hospital Bristol, Gloucester, Yeovil, Queen Elizabeth II Hertfordshire, Pinderfields Yorkshire, Churchill Oxford, Alexandra Redditch, George Eliot, Russells Hall, Walsall, New Cross Wolverhampton, Heartlands Birmingham, City Birmingham, Weston General, Royal United Bath, Royal Devon and Exeter. CH acknowledges support from the NIHR Oxford cognitive health Clinical Research Facility.

Contributors

All authors contributed substantially to conception and design, or acquisition of data or analysis and interpretation of data. All authors drafted or revised the article critically for important intellectual content. All authors gave final approval of the version to be published.

Funding

Some of the work outlined in this report was funded by the National Institute for Health Research (NIHR).

Disclaimer

The views expressed are those of the authors and not necessarily those of the NIHR, the NHS or the Department of Health.

Competing interests

None declared.

Patient consent

Not required.

Ethics approval

This study had ethical approval from The West Midlands and Solihull Research Ethics Committee (10/H1/206/4).

Provenance and peer review

Not commissioned; externally peer reviewed.

Data sharing statement

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Author note

The COREQ reporting guidelines were followed.

Open access

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

REFERENCES

1. Atkinson MA, Eisenbarth GS. Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet 2001;358:221–9.
2. Campbell-Thompson M, Fu A, Kaddis JS, et al. Insulins and β-Cell Mass in the Natural History of Type 1 Diabetes. Diabetes 2016;65:719–31.
3. Narendran P, Solomon TR, Kennedy A, et al. The time has come to test the beta cell preserving effects of exercise in patients with new onset type 1 diabetes. Diabetologia 2015;58:10–18.
4. DAFNE Study Group. Training in flexible, intensive insulin management to enable dietary freedom in people with type 1 diabetes: dose adjustment for normal eating (DAFNE) randomised controlled trial. BMJ 2002;325:746.
5. Chaturvedi N, Spille A-K, Stephenson JM, et al. Effect of lisinopril on progression of retinopathy in patients with type 1 diabetes. The Lancet 1998;351:28–31.
6. Farmer AJ, Gibson OJ, Dudley C, et al. A Randomized Controlled Trial of the Effect of Real-Time Telemedicine Support on Glycemic Control in Young Adults With Type 1 Diabetes (ISRCTN 46889446). Diabetes Care 2005;28:2697–9.
7. Alhadi Ali M, Liu YF, Arif S, et al. Metabolic and immune effects of immunotherapy with proinsulin peptide in human new-onset type 1 diabetes. Sci Transl Med 2017;9:402.
8. Rigby MR, Harris KM, Pinkney A, et al. Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients. J Clin Invest 2015;125:3285–96.
9. Umpierre D, Ribeiro PA, Kramer CK, et al. Physical activity advice only or structured exercise training and association with HbA1c levels in type 2 diabetes: a systematic review and meta-analysis. JAMA 2011;305:1790–9.
10. Ross S, Grant A, Counsell C, et al. Barriers to participation in randomised controlled trials: a systematic review. J Clin Epidemiol 1999;52:1143–56.
11. Gautier VC, Tierney JF, Stening S, et al. Strategies to improve retention in randomised trials: a Cochrane systematic review and meta-analysis. BMJ Open 2014;4:2.
12. Lascar N, Kennedy A, Jackson N, et al. Exercise to preserve beta cell function in recent-onset type 1 diabetes mellitus (EXTOD) – a study protocol for a pilot randomised controlled trial. Trials 2013;14:180.
13. Kennedy A, Narendran P, Andrews RC, et al. Attitudes and barriers to exercise in adults with a recent diagnosis of type 1 diabetes: a qualitative study of participants in the Exercise for Type 1 Diabetes (EXTOD) study. BMJ Open 2018;8:e017813.
14. Narendran P, Jackson N, Daley A, et al. Exercise to preserve β-cell function in recent-onset Type 1 diabetes mellitus (EXTOD) - a randomized controlled pilot trial. Diabet Med 2017;34:1521–31.
15. Bryman A. Social research methods. Oxford: Oxford University Press, 2010.
16. Gale NK, Heath G, Cameron E, et al. Using the framework method for the analysis of qualitative data in multi-disciplinary health research. BMC Med Res Methodol 2013;13:117.
17. Ritchie J, Lewis J. Qualitative research practice: a guide for social science students and researchers. London: Sage Publications, 2003.
18. Cheyette C, Balolia Y. Carbs and Cals: Chello Publishing. 2014. www.carbsandcals.com/products/carb-and-calorie-counter-book/ (accessed 12 Nov 2014).
19. Johansson K, Ekebergh M, Dahlberg K. A lifeworld phenomenological study of the experience of falling ill with diabetes. Int J Nurs Stud 2009;46:197–203.
20. Kato A, Fujimaki Y, Fujimori S, et al. A qualitative study on the impact of internalized stigma on type 2 diabetes self-management. Patient Educ Couns 2016;99:1233–9.
21. Featherstone K, Donovon JL. Random allocation or allocation at random? Patients’ perspectives of participation in a randomised controlled trial. BMJ 1998;317:1177–80.
22. Snehoreen C, Windle R, Cox K. What do Patients want from Multimedia Resources? Innovating Information Delivery for Potential Clinical Trials Participants. Patient Educ Couns 2012.
23. Partridge AH, Winer EP. Informing clinical trial participants about study results. JAMA 2002;288:363–5.
24. Lasserson D, Fox R, Farmer A. Late onset type 1 diabetes. BMJ 2012;344:e2927.
25. Stone CA, Palmer JH, Saxby PJ, et al. Reducing non-attendance at outpatient clinics. J R Soc Med 1999;92:114–8.
26. Bower P, Brueton V, Gamble C, et al. Interventions to improve recruitment and retention in clinical trials: a survey and workshop to assess current practice and future priorities. Trials 2014;15:399.

27. Mills EJ, Seely D, Rachlis B, et al. Barriers to participation in clinical trials of cancer: a meta-analysis and systematic review of patient-reported factors. Lancet Oncol 2006;7:141–8.

28. Cox K. Enhancing cancer clinical trial management: recommendations from a qualitative study of trial participants’ experiences. Psychooncology 2000;9:314–22.

29. Friedman DB, Foster C, Bergeron CD, et al. A qualitative study of recruitment barriers, motivators, and community-based strategies for increasing clinical trials participation among rural and urban populations. Am J Health Promot 2015;29:332–8.

30. Gul RB, Ali PA. Clinical trials: the challenge of recruitment and retention of participants. J Clin Nurs 2010;19:227–33.

31. Report EE. Patients’ reasons for participation in clinical trials and effect of trial participation on patient outcomes. Plymouth Meeting, PA: ECRI Health Technology Assessment Information Service, 2002.

32. Thomas NJ, Jones SE, Weedon MN, et al. Frequency and phenotype of type 1 diabetes in the first six decades of life: a cross-sectional, genetically stratified survival analysis from UK Biobank. Lancet Diabetes Endocrinol 2018;6:122–9.

33. Thunander M, Petersson C, Jonzon K, et al. Incidence of type 1 and type 2 diabetes in adults and children in Kronoberg, Sweden. Diabetes Res Clin Pract 2008;82:247–55.

34. Fagot-Campagna A, Pettitt DJ, Engelgau MM, et al. Type 2 diabetes among North adolescents: an epidemiologic health perspective. J Pediatr 2000;136:664–72.

35. Serrano-Rios M, Goday A, Martinez Larrad T, Martinez L. Migrant populations and the incidence of type 1 diabetes mellitus: an overview of the literature with a focus on the Spanish-heritage countries in Latin America. Diabetes Metab Res Rev 1999;15:113–32.

36. Bristol City Council. The population of bristol. Bristol, 2014.

37. Council TDB. Taunton deane borough council equalities information report 2013 a profile of taunton deane – part one. Taunton, 2013.

38. Council GC. Population analysis for the protected characteristics: Gloucestershire, 2010.